Table 2 Summary of clinical studies evaluating tucatinib combination approaches in HER2+ metastatic breast cancer patients with brain metastasis
From: The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Treatment(s) | Parameter(s) | Study design and finding(s) |
|---|---|---|
Tucatinib + trastuzumab + capecitabine [47] | OS | To evaluate safety. The OS was 20.7 months with the tucatinib-combination |
Tucatinib + T-DMI [77] | mPFS | Phase I dose-escalation study to evaluate effect. The mPFS was 8.2 months |
Tucatinib + trastuzumab [78] | MTD | Phase I dose-escalation study to evaluate response. The combination therapy was tolerable and effective in HER2+ breast cancer patients having brain metastases |
Tucatinib + capecitabine, tucatinib + trastuzumab, tucatinib + capecitabine + trastuzumab [46] | mPFS | Phase I dose-escalation study to evaluate response. ORR of tucatinib + capecitabine was 83%, tucatinib + trastuzumab was 40%, and tucatinib + capecitabine + trastuzumab was 61%. The mPFS of the triple combination in patients with no brain metastasis was 7.8 months; however, it was 6.7 months in patients with brain metastasis |
Tucatinib + trastuzumab + capecitabine [79] | OS | Phase II study to evaluate safety and efficacy. The median OS was 11.9 months and the median time to CNS progression 6.9 months |